Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acteinib + bevacizumab for EGFR-mutant lung adenocarcinoma with brain metastases
ChiCTR2000033102Phase 2Not yet recruiting
- Sponsor
- Maoming People's Hospital
- Start
- Jun 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of icotinib and bevacizumab in Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by Maoming People's Hospital. Primary endpoints: Tumor size and Control time of intracranial metastatic foci. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
icotinibbevacizumab
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000033102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033102.